Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.
2.

Response to 'Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomized study over 21 months'.

Gonzalez-Gay MA, Gonzalez-Juanatey C, Miranda-Filloy JA, Martin J, Garcia-Unzueta MT, Llorca J.

Arthritis Res Ther. 2011 Apr 27;13(2):404. doi: 10.1186/ar3301. No abstract available.

3.

Relationship between growth hormone-IGF-I-IGFBP-3 axis and serum leptin levels with bone mass and body composition in patients with rheumatoid arthritis.

Toussirot E, Nguyen NU, Dumoulin G, Aubin F, Cédoz JP, Wendling D.

Rheumatology (Oxford). 2005 Jan;44(1):120-5. Epub 2004 Oct 5.

PMID:
15466894
4.

Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis.

Serelis J, Kontogianni MD, Katsiougiannis S, Bletsa M, Tektonidou MG, Skopouli FN.

Clin Rheumatol. 2008 Jun;27(6):795-7. doi: 10.1007/s10067-008-0855-7. Epub 2008 Feb 28.

PMID:
18305977
5.

Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis.

Derdemezis CS, Filippatos TD, Voulgari PV, Tselepis AD, Drosos AA, Kiortsis DN.

Fundam Clin Pharmacol. 2009 Oct;23(5):595-600. doi: 10.1111/j.1472-8206.2009.00717.x. Epub 2009 Jun 25.

PMID:
19563510
6.

Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone.

Verhoeven AC, Boers M, te Koppele JM, van der Laan WH, Markusse HM, Geusens P, van der Linden S.

Rheumatology (Oxford). 2001 Nov;40(11):1231-7.

PMID:
11709606
7.

Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis.

Popa C, Netea MG, de Graaf J, van den Hoogen FH, Radstake TR, Toenhake-Dijkstra H, van Riel PL, van der Meer JW, Stalenhoef AF, Barrera P.

J Rheumatol. 2009 Apr;36(4):724-30. doi: 10.3899/jrheum.080626. Epub 2009 Feb 27.

PMID:
19273452
8.

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.

Karlsson JA, Neovius M, Nilsson JÅ, Petersson IF, Bratt J, van Vollenhoven RF, Ernestam S, Geborek P.

Ann Rheum Dis. 2013 Dec;72(12):1927-33. doi: 10.1136/annrheumdis-2012-202062. Epub 2012 Nov 29.

PMID:
23196701
9.

Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.

Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T.

Ann Rheum Dis. 2008 Mar;67(3):353-7. Epub 2007 Jul 20.

PMID:
17644538
10.
11.

Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial.

Eriksson JK, Neovius M, Bratt J, Petersson IF, van Vollenhoven RF, Geborek P, Ernestam S.

JAMA Intern Med. 2013 Aug 12;173(15):1407-14. doi: 10.1001/jamainternmed.2013.7801.

PMID:
23817631
12.

Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment.

Briot K, Garnero P, Le Henanff A, Dougados M, Roux C.

Ann Rheum Dis. 2005 Aug;64(8):1137-40. Epub 2005 Jan 7.

13.
14.

Energy-restricted diet benefits body composition but degrades bone integrity in middle-aged obese female rats.

Shen CL, Zhu W, Gao W, Wang S, Chen L, Chyu MC.

Nutr Res. 2013 Aug;33(8):668-76. doi: 10.1016/j.nutres.2013.05.008. Epub 2013 Jun 24.

PMID:
23890357
15.

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.

van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Cöster L, Waltbrand E, Zickert A, Theander J, Thörner A, Hellström H, Teleman A, Dackhammar C, Akre F, Forslind K, Ljung L, Oding R, Chatzidionysiou A, Wörnert M, Bratt J.

Lancet. 2009 Aug 8;374(9688):459-66. doi: 10.1016/S0140-6736(09)60944-2.

PMID:
19665644
16.

The influence of ghrelin, adiponectin, and leptin on bone mineral density in healthy postmenopausal women.

Jürimäe J, Jürimäe T, Leppik A, Kums T.

J Bone Miner Metab. 2008;26(6):618-23. doi: 10.1007/s00774-008-0861-5. Epub 2008 Nov 1.

PMID:
18979162
17.

Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis.

Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, Dijkmans BA, Woolf AD, Kvien TK, Lems WF.

Ann Rheum Dis. 2006 Nov;65(11):1495-9. Epub 2006 Apr 10.

18.

Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.

Lange U, Teichmann J, Müller-Ladner U, Strunk J.

Rheumatology (Oxford). 2005 Dec;44(12):1546-8. Epub 2005 Nov 1.

PMID:
16263785
19.

Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.

Möttönen T, Hannonen P, Korpela M, Nissilä M, Kautiainen H, Ilonen J, Laasonen L, Kaipiainen-Seppänen O, Franzen P, Helve T, Koski J, Gripenberg-Gahmberg M, Myllykangas-Luosujärvi R, Leirisalo-Repo M; FIN-RACo Trial Group. FINnish Rheumatoid Arthritis Combination therapy.

Arthritis Rheum. 2002 Apr;46(4):894-8.

PMID:
11953964
20.

Plasma leptin and neuropeptide Y concentrations in patients with rheumatoid arthritis treated with infliximab, a TNF-α antagonist.

Kopec-Medrek M, Kotulska A, Widuchowska M, Adamczak M, Więcek A, Kucharz EJ.

Rheumatol Int. 2012 Nov;32(11):3383-9. doi: 10.1007/s00296-011-2182-6. Epub 2011 Nov 3.

Supplemental Content

Support Center